HB-adMSC Allogeneic is under clinical development by Hope Biosciences and currently in Phase II for Coronavirus Disease 2019 (COVID-19). According to GlobalData, Phase II drugs for Coronavirus Disease 2019 (COVID-19) have a 76% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how HB-adMSC Allogeneic’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
HB-adMSC Allogeneic overview
Cell therapy is under development for the treatment of cerebral palsy, Parkinson's disease, coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), long COVID and acute kidney injury. The therapeutic candidate comprises of intravenously administered allogeneic adipose-derived mesenchymal stem cells.
It was also under development for the multiple sclerosis.
Hope Biosciences overview
Hope Biosciences is discovering and developing adult stem cell solutions for treating chronic degenerative diseases. The company is headquartered in Sugar Land, Texas, the US.
For a complete picture of HB-adMSC Allogeneic’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
